BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35603926)

  • 1. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
    Meyer HJ; Wienke A; Surov A
    Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Meyer HJ; Strobel A; Wienke A; Surov A
    Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
    Meyer HJ; Wienke A; Zamsheva M; Surov A
    Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Nutrition; 2021; 91-92():111417. PubMed ID: 34399402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
    Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
    March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
    Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.
    Surov A; Pech M; Gessner D; Mikusko M; Fischer T; Alter M; Wienke A
    Clin Nutr; 2021 Oct; 40(10):5298-5310. PubMed ID: 34536638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
    Surov A; Strobel A; Borggrefe J; Wienke A
    Eur Radiol; 2023 Sep; 33(9):6426-6437. PubMed ID: 36929392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
    Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019.
    Meyer HJ; Wienke A; Surov A
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):159-168. PubMed ID: 35018725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
    Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
    HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.
    Anabtawi NM; Pasala MS; Grimshaw AA; Kharel P; Bal S; Godby K; Siwakoti A; Buford TW; Bhatia S; Costa LJ; Williams GR; Giri S
    J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38558541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
    Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
    Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT assessment of preoperative nutritional status in gastric cancer: severe low skeletal muscle mass and obesity-related low skeletal muscle mass are unfavorable factors of postoperative complications.
    Fang Z; Du F; Shang L; Liu J; Ren F; Liu Y; Wu H; Liu Y; Li P; Li L
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):317-324. PubMed ID: 33063547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
    Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer - a Meta-analysis.
    Thormann M; Hinnerichs M; Barajas Ordonez F; Saalfeld S; Perrakis A; Croner R; Omari J; Pech M; Zamsheva M; Meyer HJ; Wienke A; Surov A
    Acad Radiol; 2023 Aug; 30(8):1552-1561. PubMed ID: 36564257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.